Trial Profile
Pilot study (Phase II) of Pomalidomide, oral Desamethasone and very low-dose Cyclophosphamide in patients with refractory Multiple Myeloma who have received Lenalidomide and Bortezomib
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Dec 2019 Status changed from recruiting to discontinued.
- 09 Nov 2016 New trial record